Comparative evaluation of plasma biomarkers of Schistosoma haematobium infection in endemic populations from Burkina Faso.
Mireille OuedraogoJana Christina HeyStan HiltVeronica Rodriguez FernandezDoris WinterRavo RazafindrakotoPytsje T HoekstraYoussouf KaboreMarco ForniliLaura BagliettoIssa NebieGovert J van DamPaul L A M CorstjensDaniela FuscoDavid ModianoFabrizio BruschiValentina Dianora ManganoPublished in: PLoS neglected tropical diseases (2024)
Infection with Schistosoma haematobium causes urogenital disease associated with organ disfunction, bleeding, pain, and higher susceptibility to infections and cancer. Timely and accurate diagnosis is crucial for prompt and appropriate treatment as well as surveillance efforts, and the use of plasma biomarkers offers important advantages over parasitological examination of urine, including increased sensitivity and the possibility to use the same specimen for multiple investigations. The present study aims to evaluate the diagnostic performance of different plasma biomarkers in endemic populations from Burkina Faso, West Africa. Schistosoma spp. Circulating Anodic Antigen (CAA), cell free S. haematobium DNA (cfDNA), class M and G antibodies against S. haematobium Soluble Worm Antigen Preparation (SWAP) and Soluble Egg Antigen (SEA) were measured in 406 plasma samples. Results of each biomarker test were compared to those of CAA, a Composite Reference Standard (CRS) and Latent Class Analysis (LCA). An identical proportion of positive samples (29%) was observed as a result of CAA and cfDNA testing, with a substantial agreement (84%, Cohen k = 0.62) between the results of the two tests, and a comparable agreement with the results of CRS and LCA. A higher positivity was observed, as expected, as a result of specific antibody testing (47%-72%), with IgG showing a higher agreement than IgM with the three references. Also, higher IgG levels were observed in current vs past infection, and ROC analysis identified optimal cutoff values for improved testing accuracy. This study provides compelling evidence that can inform the choice of the most appropriate diagnostic plasma biomarker for urogenital schistosomiasis in endemic areas, depending on the purpose, context, and available resources for testing. Either CAA or cfDNA testing can be used for the diagnosis of patients and for epidemiological investigations, even in absence of urine filtration microscopy, whereas anti-SWAP or anti-SEA IgG can be employed for surveillance and integrated monitoring of control interventions against poverty-associated diseases.
Keyphrases
- cell free
- public health
- end stage renal disease
- single molecule
- newly diagnosed
- circulating tumor
- prognostic factors
- ejection fraction
- physical activity
- squamous cell carcinoma
- spinal cord
- chronic pain
- atrial fibrillation
- optical coherence tomography
- peritoneal dialysis
- spinal cord injury
- combination therapy
- quality improvement
- simultaneous determination
- nucleic acid
- postoperative pain